Rimantadine HCL en es it fr

Rimantadine HCL Brand names, Rimantadine HCL Analogs

Rimantadine HCL Brand Names Mixture

  • No information avaliable

Rimantadine HCL Chemical_Formula

C19H22F2N4O3

Rimantadine HCL RX_link

http://www.rxlist.com/cgi/generic2/sparfloxacin.htm

Rimantadine HCL fda sheet

Rimantadine_HCL FDA

Rimantadine HCL msds (material safety sheet)

Rimantadine HCL Synthesis Reference

No information avaliable

Rimantadine HCL Molecular Weight

392.4 g/mol

Rimantadine HCL Melting Point

No information avaliable

Rimantadine HCL H2O Solubility

Practically insoluble

Rimantadine HCL State

Solid

Rimantadine HCL LogP

1.695

Rimantadine HCL Dosage Forms

Tablets (200-mg round, white, film-coated)

Rimantadine HCL Indication

For the treatment of adults with the following infections caused by susceptible strains microorganisms: community-acquired pneumonia (caused by Chlamydia pneumoniae, Haemophilus influenzae, Haemophilus parainfluenzae, Moraxella catarrhalis, Mycoplasma pneumoniae, or Streptococcus pneumoniae) and acute bacterial exacerbations of chronic bronchitis (caused by Chlamydia pneumoniae, Enterobacter cloacae, Haemophilus influenzae, Haemophilus parainfluenzae, Klebsiella pneumoniae, Moraxella catarrhalis, Staphylococcus aureus, or Streptococcus pneumoniae).

Rimantadine HCL Pharmacology

Sparfloxacin is a synthetic fluoroquinolone broad-spectrum antimicrobial agent in the same class as ofloxacin and norfloxacin. Sparfloxacin has in vitro activity against a wide range of gram-negative and gram-positive microorganisms. Sparfloxacin exerts its antibacterial activity by inhibiting DNA gyrase, a bacterial topoisomerase. DNA gyrase is an essential enzyme which controls DNA topology and assists in DNA replication, repair, deactivation, and transcription. Quinolones differ in chemical structure and mode of action from (beta)-lactam antibiotics. Quinolones may, therefore, be active against bacteria resistant to (beta)-lactam antibiotics. Although cross-resistance has been observed between sparfloxacin and other fluoroquinolones, some microorganisms resistant to other fluoroquinolones may be susceptible to sparfloxacin. In vitro tests show that the combination of sparfloxacin and rifampin is antagonistic against Staphylococcus aureus.

Rimantadine HCL Absorption

Well absorbed following oral administration with an absolute oral bioavailability of 92%. Unaffected by administration with milk or food, however concurrent administration of antacids containing magnesium hydroxide and aluminum hydroxide reduces the oral bioavailability of sparfloxacin by as much as 50%.

Rimantadine HCL side effects and Toxicity

Single doses of sparfloxacin were relatively non-toxic via the oral route of administration in mice, rats, and dogs. No deaths occurred within a 14-day post-treatment observation period at the highest oral doses tested, up to 5000 mg/kg in either rodent species, or up to 600 mg/kg in the dog. Clinical signs observed included inactivity in mice and dogs, diarrhea in both rodent species, and vomiting, salivation, and tremors in dogs.

Rimantadine HCL Patient Information

Rimantadine HCL Organisms Affected

Enteric bacteria and other eubacteria